Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Nutrients ; 13(2)2021 Jan 27.
Artigo em Inglês | MEDLINE | ID: mdl-33513893

RESUMO

The worldwide increase in the number of patients with dementia is becoming a growing problem, while Alzheimer's disease (AD), a primary neurodegenerative disorder, accounts for more than 70% of all dementia cases. Research on the prevention or reduction of AD occurrence through food ingredients has been widely conducted. In particular, histidine-containing dipeptides, also known as imidazole dipeptides derived from meat, have received much attention. Imidazole dipeptides are abundant in meats such as poultry, fish, and pork. As evidenced by data from recent human intervention trials conducted worldwide, daily supplementation of carnosine and anserine, which are both imidazole dipeptides, can improve memory loss in the elderly and reduce the risk of developing AD. This article also summarizes the latest researches on the biochemical properties of imidazole dipeptides and their effects on animal models associated with age-related cognitive decline. In this review, we focus on the results of human intervention studies using supplements of poultry-derived imidazole dipeptides, including anserine and carnosine, affecting the preservation of cognitive function in the elderly, and discuss how imidazole dipeptides act in the brain to prevent age-related cognitive decline and the onset of dementia.


Assuntos
Cognição/efeitos dos fármacos , Dipeptídeos/farmacologia , Imidazóis/farmacologia , Idoso , Doença de Alzheimer/tratamento farmacológico , Animais , Anserina/farmacologia , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Carnosina/farmacologia , Disfunção Cognitiva/tratamento farmacológico , Suplementos Nutricionais , Modelos Animais de Doenças , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto
2.
Nutrients ; 12(12)2020 Nov 26.
Artigo em Inglês | MEDLINE | ID: mdl-33256220

RESUMO

Matcha Green Tea Powder contains a variety of active ingredients beneficial to health, such as tea catechins, lutein and vitamin K. It is also known that these ingredients confer benefits upon cognitive functions of elderly people. Therefore, we aimed to investigate the relationship between a daily supplementation of Matcha and the change in cognitive functions of community-dwelling elderly people. A randomized, double-blind, placebo-controlled 12-week trial was performed. Sixty-one participants were recruited and randomly assigned to receive test drink containing 3g powder from fresh Matcha or placebo powder per day. Changes in cognitive function were assessed utilizing a psychometric test battery. Daily food intake was assessed by a Brief-type Self-administered Diet History Questionnaire (BDHQ). In the gender-specific analysis, a significant cognitive enhancement was observed in the Montreal Cognitive Assessment (MoCA) score in the active group of women. In dietary analysis, we found a significant inverse correlation between consumption of vitamin K in daily diet, excluding test drinks, and change in MoCA. The present study suggests that daily supplementation of Matcha Green Tea Powder has protective effects against cognitive decline in community-dwelling elderly women.


Assuntos
Antioxidantes/farmacologia , Cognição/efeitos dos fármacos , Disfunção Cognitiva/prevenção & controle , Dieta/métodos , Chá , Idoso , Idoso de 80 Anos ou mais , Envelhecimento , Método Duplo-Cego , Feminino , Humanos , Vida Independente , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Psicometria , Fatores Sexuais
3.
Nutrients ; 11(7)2019 Jul 17.
Artigo em Inglês | MEDLINE | ID: mdl-31319510

RESUMO

BACKGROUND: Oral supplementation of anserine/carnosine helps preserve cognitive functions in healthy older adults. Mild cognitive impairment (MCI) is a transition between cognitive-normal and dementia. Therefore, it needs to investigate whether anserine/carnosine supplementation (ACS) has effects on subjects with MCI. METHODS: A randomized, double-blind, placebo-controlled 12-week trial was performed. Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1). Evaluation of cognitive change was conducted utilizing a psychometric test battery. RESULTS: The score improvement in the global Clinical Dementia Rating (gloCDR) was superior in the active group than placebo (p = 0.023). No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer's Disease Assessment Scale (ADAS). When APOE4 positive (APOE4 (+)) or negative (APOE4 (-)) subjects were separately analyzed, beneficial change in the APOE4 (+) subjects was observed in MMSE (p = 0.025) as well as in gloCDR (p = 0.026). CONCLUSIONS: The present study might suggest that protective effects against cognitive decline in APOE4 (+) MCI subjects exist.


Assuntos
Anserina/administração & dosagem , Apolipoproteína E4/metabolismo , Carnosina/administração & dosagem , Disfunção Cognitiva , Idoso , Idoso de 80 Anos ou mais , Peptídeos beta-Amiloides/sangue , Cognição/efeitos dos fármacos , Suplementos Nutricionais , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
4.
Nutrients ; 9(11)2017 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-29088099

RESUMO

Our goal was to determine whether anserine/carnosine supplementation (ACS) suppresses chemokine levels in elderly people. In a double-blind randomized controlled trial, volunteers were assigned to the ACS or placebo group (1:1). Sixty healthy elderly volunteers (active, n = 30; placebo, n = 30) completed the study. The ACS group was administered 1.0 g of anserine/carnosine (3:1) for 3 months. A microarray analysis and subsequent quantitative real-time polymerase chain reaction (qRT-PCR) analysis of peripheral blood mononuclear cells (PBMCs) showed decreased expression of CCL24, an inflammatory chemokine (p < 0.05). Verbal memory, assessed using the Wechsler memory scale-logical memory, was preserved in the ACS group. An age-restricted sub-analysis showed significant verbal memory preservation by ACS in participants who were in their 60s (active, n = 12; placebo, n = 9; p = 0.048) and 70s (active, n = 7; placebo, n = 11; p = 0.017). The suppression of CCL24 expression was greatest in people who were in their 70s (p < 0.01). There was a significant correlation between the preservation of verbal memory and suppression of CCL24 expression in the group that was in the 70s (Poisson correlation, r = 0.46, p < 0.05). These results suggest that ACS may preserve verbal episodic memory, probably owing to CCL24 suppression in the blood, especially in elderly participants.


Assuntos
Envelhecimento , Anserina/administração & dosagem , Carnosina/administração & dosagem , Quimiocina CCL24/sangue , Suplementos Nutricionais , Mediadores da Inflamação/sangue , Leucócitos Mononucleares/efeitos dos fármacos , Transtornos da Memória/prevenção & controle , Adulto , Fatores Etários , Idoso , Envelhecimento/sangue , Envelhecimento/imunologia , Envelhecimento/psicologia , Anserina/efeitos adversos , Biomarcadores/sangue , Carnosina/efeitos adversos , Quimiocina CCL24/genética , Cognição/efeitos dos fármacos , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Regulação para Baixo , Combinação de Medicamentos , Feminino , Humanos , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/metabolismo , Masculino , Transtornos da Memória/sangue , Transtornos da Memória/diagnóstico , Transtornos da Memória/psicologia , Memória Episódica , Pessoa de Meia-Idade , Fatores de Tempo , Tóquio , Resultado do Tratamento
5.
J Alzheimers Dis ; 50(1): 149-59, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26682691

RESUMO

Our goal in this study was to determine whether or not anserine/carnosine supplementation (ACS) is capable of preserving cognitive function of elderly people. In a double-blind randomized controlled trial, volunteers were randomly assigned to an ACS or placebo group at a 1:1 ratio. The ACS group took 1.0 g of an anserine/carnosine (3:1) formula daily for 3 months. Participants were evaluated by psychological tests before and after the 3-month supplementation period. Thirty-nine healthy elderly volunteers (60-78 years old) completed the follow-up tests. Among the tests, delayed recall verbal memory assessed by the Wechsler Memory Scale-Logical Memory showed significant preservation in the ACS group, compared to the placebo group (p = 0.0128). Blood analysis revealed a decreased secretion of inflammatory cytokines, including CCL-2 and IL-8, in the ACS group. MRI analysis using arterial spin labeling showed a suppression in the age-related decline in brain blood flow in the posterior cingulate cortex area in the ACS group, compared to the placebo group (p = 0.0248). In another randomized controlled trial, delayed recall verbal memory showed significant preservation in the ACS group, compared to the placebo group (p = 0.0202). These results collectively suggest that ACS may preserve verbal episodic memory and brain perfusion in elderly people, although further study is needed.


Assuntos
Envelhecimento , Anserina/farmacologia , Carnosina/farmacologia , Memória Episódica , Aprendizagem Verbal/efeitos dos fármacos , Adulto , Idoso , Encéfalo/anatomia & histologia , Encéfalo/efeitos dos fármacos , Citocinas/sangue , Citocinas/genética , Suplementos Nutricionais , Método Duplo-Cego , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Processamento de Imagem Assistida por Computador , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Análise de Sequência com Séries de Oligonucleotídeos
6.
Invest Ophthalmol Vis Sci ; 43(9): 2916-22, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12202510

RESUMO

PURPOSE: To characterize in SV40-immortalized human corneal epithelial cells (tHCEC) osmosensitive taurine transporter gene and protein expression as well as its functional activity. To evaluate whether medium supplementation with taurine improves cell viability during a hypertonic challenge. METHODS: tHCEC were preincubated for up to 48 hours in hypertonic DMEM medium (i.e., up to 500 mosmol/kg). Taurine uptake was monitored through measurements of intracellular [3H]taurine accumulation. Gene and protein expression was detected by Northern and Western blot analyses, respectively. An amino acid analyzer measured intracellular cold taurine content. The live/dead assay evaluated with confocal microscopy determined cell viability. RESULTS: Na+-dependent taurine uptake occurred in an isotonic (310 mosmol/kg) medium. The apparent Michaelis-Menten constant, K(t), for taurine was 4.6 micro M, and uptake increased as a function of exposure time and rises in osmolality. Exposure for 12 hours to a 450 mosmol/kg medium increased uptake by 4.1-fold. However, after 48 hours of exposure to this medium, taurine uptake returned to its isotonic level. With time, biphasic changes occurred in taurine transporter gene and protein expression and taurine transport activity as well as elevating intracellular taurine content by 4.5-fold. Taurine medium supplementation for 48 hours improved cell viability. CONCLUSIONS: tHCEC express Na+-dependent osmosensitive taurine transport activity. The hypertonic-induced biphasic effects on gene and protein expression as well as transport activity suggest feedback regulation of these responses. Rises in intracellular taurine do not appear to be essential for osmoregulation, but instead enhance cell survival perhaps through a membrane stabilizer or an antioxidant effect.


Assuntos
Proteínas de Transporte/biossíntese , Epitélio Corneano/metabolismo , Glicoproteínas de Membrana/biossíntese , Proteínas de Membrana Transportadoras , Northern Blotting , Western Blotting , Proteínas de Transporte/genética , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Retroalimentação Fisiológica , Humanos , Soluções Hipertônicas , Soluções Isotônicas , Glicoproteínas de Membrana/genética , Microscopia Confocal , Concentração Osmolar , Taurina/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA